By VETTAPHARMA reporter: Sanofi announced on January 15, 2026, that China’s National Medical Products Administration has approved two of its licensed innovative medicines — Myqorzo (aficamten) and Redemplo (plozasiran) — for use in the Chinese market, reinforcing the company’s commitment to addressing unmet medical needs in complex conditions.
Myqorzo has been approved for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), a genetic heart disorder in which the heart muscle becomes abnormally thick, potentially limiting the heart’s ability to pump blood. Redemplo has been approved for the reduction of triglyceride levels in adult patients with familial chylomicronemia syndrome (FCS), a rare and severe condition characterized by extremely high triglycerides on the basis of dietary control.
Olivier Charmeil, Executive Vice President of General Medicines at Sanofi, said the dual approvals underscore the company’s long-term commitment to bringing innovative and transformative treatments to patients in Greater China. Both medicines represent important advances in treatment options for people living with these complex diseases and had been granted breakthrough therapies in China.
Myqorzo is described as a selective small-molecule cardiac myosin inhibitor that improves functional capacity and relieve symptoms in patients with symptomatic oHCM. The approval was based on positive findings from the pivotal SEQUOIA-HCM Phase 3 study (clinical study identifier: NCT05186818) in patients with symptomatic oHCM.
Redemplo is a small-interfering RNA (siRNA) medicine that suppresses the production of apolipoprotein C-III, a key protein involved in triglyceride metabolism. Its Chinese approval follows supportive results from the PALISADE Phase 3 study (clinical study identifier: NCT05089084) in patients with genetically confirmed or clinically diagnosed FCS.
According to the press release, these approvals reflect Sanofi’s broader ambition to provide transformative medicines to patients in disease areas with substantial unmet medical needs, while further strengthening its presence in the Chinese pharmaceutical market.
Source credit:
- Sanofi. (2026, January 15). Myqorzo and Redemplo approved in China [Press release]. Sanofi. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. The platform and its contributors disclaim any liability for actions taken based on the information presented.
